Market reactionShares rose 11% on Nov 6.
Faeth Therapeutics is a clinical-stage company developing PIKTOR, an all-oral combination that blocks the PI3K/AKT/mTOR pathway, for endometrial and breast cancer; it is not approved.
Faeth's investment case rests on PIKTOR, an investigational oral combination targeting PI3K-alpha and mTORC1/2. Earlier activity with paclitaxel supports further development, but PIK-201 must demonstrate meaningful benefit in second-line advanced endometrial cancer, with topline data anticipated by year-end 2026. PIK-101 provides a breast cancer opportunity, with interim data anticipated in 2027. Management expects existing capital to fund both readouts, subject to spending assumptions; further financing remains necessary for continued development.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: PIK-201 confirms activity in endometrial cancer
Does PIKTOR produce durable responses with manageable side effects in second-line advanced endometrial cancer?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
PIKTOR endometrial cancer data remain due by year-end; breast cancer development continues
PIKTOR's PI3K/AKT/mTOR inhibition targets mutation-selected endometrial and breast cancer; Phase 2 topline data will confirm or refute the 71% Phase 1b response signal
PIKTOR's Phase 2 readout in PI3K-mutant endometrial cancer will determine whether Sensei's post-pivot thesis holds after abandoning solnerstotug
Acquisition of Faeth Therapeutics completed
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Breast and gynecologic cancers, Other cancers, Rare genetic and metabolic diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
4 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.